Diplomat Pharmacy (DPLO) Tops Q2 EPS by 2c

Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.12 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.90-$0.95, versus prior guidance of $0.88-$0.95 and the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.5-4.9 billion, versus the consensus of $4.76 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea